JP2019515052A - 化学的除神経から生じる副作用の処置 - Google Patents

化学的除神経から生じる副作用の処置 Download PDF

Info

Publication number
JP2019515052A
JP2019515052A JP2019512184A JP2019512184A JP2019515052A JP 2019515052 A JP2019515052 A JP 2019515052A JP 2019512184 A JP2019512184 A JP 2019512184A JP 2019512184 A JP2019512184 A JP 2019512184A JP 2019515052 A JP2019515052 A JP 2019515052A
Authority
JP
Japan
Prior art keywords
alkyl
anticholinesterase
composition
muscle
botulinum toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019512184A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515052A5 (https=
Inventor
メアリー・ガードナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delnova inc
Original Assignee
Delnova inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delnova inc filed Critical Delnova inc
Publication of JP2019515052A publication Critical patent/JP2019515052A/ja
Publication of JP2019515052A5 publication Critical patent/JP2019515052A5/ja
Priority to JP2022063952A priority Critical patent/JP2022088660A/ja
Priority to JP2024067205A priority patent/JP2024099644A/ja
Priority to JP2025064212A priority patent/JP2025108527A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
JP2019512184A 2016-05-13 2017-05-15 化学的除神経から生じる副作用の処置 Pending JP2019515052A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022063952A JP2022088660A (ja) 2016-05-13 2022-04-07 化学的除神経から生じる副作用の処置
JP2024067205A JP2024099644A (ja) 2016-05-13 2024-04-18 化学的除神経から生じる副作用の処置
JP2025064212A JP2025108527A (ja) 2016-05-13 2025-04-09 化学的除神経から生じる副作用の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662336344P 2016-05-13 2016-05-13
US62/336,344 2016-05-13
PCT/US2017/032636 WO2017197382A1 (en) 2016-05-13 2017-05-15 Treating of side-effects resulting from chemodenervation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022063952A Division JP2022088660A (ja) 2016-05-13 2022-04-07 化学的除神経から生じる副作用の処置

Publications (2)

Publication Number Publication Date
JP2019515052A true JP2019515052A (ja) 2019-06-06
JP2019515052A5 JP2019515052A5 (https=) 2020-06-25

Family

ID=60266879

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019512184A Pending JP2019515052A (ja) 2016-05-13 2017-05-15 化学的除神経から生じる副作用の処置
JP2022063952A Pending JP2022088660A (ja) 2016-05-13 2022-04-07 化学的除神経から生じる副作用の処置
JP2024067205A Pending JP2024099644A (ja) 2016-05-13 2024-04-18 化学的除神経から生じる副作用の処置
JP2025064212A Pending JP2025108527A (ja) 2016-05-13 2025-04-09 化学的除神経から生じる副作用の処置

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022063952A Pending JP2022088660A (ja) 2016-05-13 2022-04-07 化学的除神経から生じる副作用の処置
JP2024067205A Pending JP2024099644A (ja) 2016-05-13 2024-04-18 化学的除神経から生じる副作用の処置
JP2025064212A Pending JP2025108527A (ja) 2016-05-13 2025-04-09 化学的除神経から生じる副作用の処置

Country Status (10)

Country Link
US (2) US11129822B2 (https=)
EP (1) EP3454855B1 (https=)
JP (4) JP2019515052A (https=)
KR (2) KR20190008225A (https=)
CN (2) CN109414434A (https=)
AU (2) AU2017263850A1 (https=)
BR (1) BR112018073388A2 (https=)
CA (1) CA3023408A1 (https=)
IL (1) IL262916A (https=)
WO (1) WO2017197382A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021502981A (ja) * 2017-11-15 2021-02-04 デルノバ・インコーポレイテッドＤｅｌＮｏｖａ，Ｉｎｃ． ボツリヌス治療の副作用の処置
WO2025226839A2 (en) * 2024-04-23 2025-10-30 New York University Auf1 compositions and methods for promoting generation of neuromuscular junctions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150224094A1 (en) * 2012-09-10 2015-08-13 Ophirex, Inc. Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925856A (en) * 1987-07-28 1990-05-15 Sri International Aldoxime-substituted imidazolium derivatives useful in the treatment of poisoning by phosphorus-containing chemicals
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
EP0619814A1 (en) * 1991-12-31 1994-10-19 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
GB9410871D0 (en) * 1994-05-31 1994-07-20 Imperial College Modification of tetanus toxin for use as a transport protein
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6759552B2 (en) * 2002-03-28 2004-07-06 Council Of Scientific And Industrial Research Compound as cholinesterase inhibitor and its isolation from fungus sporotrichum species
CN1260349C (zh) * 2003-04-29 2006-06-21 云南省微生物研究所 南宁链霉菌
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
US20080090808A1 (en) * 2006-10-17 2008-04-17 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
WO2009036235A2 (en) * 2007-09-12 2009-03-19 Virginia Tech Intellectual Properties, Inc. Insecticidal carbamates exhibiting species-selective inhibition of acetylcholinesterase (ache)
CN101386818B (zh) * 2008-07-29 2011-01-19 中山大学 一种海洋真菌培养物的提取物及其制备方法和应用
JP5782439B2 (ja) * 2009-07-24 2015-09-24 リポテック, エセ.ア.Lipotec, S.A. 筋肉収縮を抑制する化合物
KR101067153B1 (ko) * 2009-10-16 2011-09-22 경상대학교산학협력단 뇌신경 세포 보호 활성 및 아세틸콜린에스테라제 저해 활성을 갖는 율피 추출물 및 그의 용도
CN102933200B (zh) 2009-12-18 2015-11-25 莱迪杜德制药公司 包含磷脂的单相凝胶组合物
JP2014520148A (ja) * 2011-06-20 2014-08-21 セントルイス ユニバーシティ 治療のための神経筋接合部への標的化
CN103524515B (zh) * 2012-07-03 2016-07-06 浙江海正药业股份有限公司 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途
LT3157534T (lt) * 2014-06-19 2022-09-12 Attillaps Holdings Acetilcholinesterazės inhibitoriai, skirti dermatologinių būklių gydymui

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150224094A1 (en) * 2012-09-10 2015-08-13 Ophirex, Inc. Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARCHINI, C., CLINICAL NEUROPHARMACOLOGY, vol. 20, no. 3, JPN6021013442, 1997, pages 279 - 280, ISSN: 0004485704 *
YOUNG, DAVID L. AND HALSTEAD, LUCINDA A., JOURNAL OF VOICE, vol. 28, no. 6, JPN6021013441, 2014, pages 830 - 834, ISSN: 0004656867 *

Also Published As

Publication number Publication date
EP3454855B1 (en) 2023-12-20
JP2025108527A (ja) 2025-07-23
US20220175753A1 (en) 2022-06-09
AU2017263850A1 (en) 2018-11-22
IL262916A (en) 2018-12-31
EP3454855A4 (en) 2019-12-25
CN109414434A (zh) 2019-03-01
JP2024099644A (ja) 2024-07-25
JP2022088660A (ja) 2022-06-14
CN119950719A (zh) 2025-05-09
CA3023408A1 (en) 2017-11-16
US20190183875A1 (en) 2019-06-20
AU2023201832A1 (en) 2023-04-27
WO2017197382A1 (en) 2017-11-16
US11129822B2 (en) 2021-09-28
EP3454855A1 (en) 2019-03-20
BR112018073388A2 (pt) 2019-07-02
KR20190008225A (ko) 2019-01-23
KR20220063197A (ko) 2022-05-17

Similar Documents

Publication Publication Date Title
JP2025108527A (ja) 化学的除神経から生じる副作用の処置
KR20010071301A (ko) 국소 진통용 트리시클릭 항우울제의 용도
US20160184340A1 (en) The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents
JP2004521111A (ja) 局所麻酔薬および使用法
CN102143687B (zh) 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途
EP1864667B1 (en) Use of prodrugs for ocular intravitreous administration
JP5822724B2 (ja) 疼痛、炎症、ニューロンもしくは血管損傷に対する生物学的マーカーおよび治療への応答、ならびにその使用方法
Skovira et al. Neuropharmacological specificity of brain structures involved in soman-induced seizures
Ohri et al. Prolonged amelioration of experimental postoperative pain by bupivacaine released from microsphere-coated hernia mesh
KR20200047655A (ko) 신경 작용제 노출을 치료하기 위해 단트롤렌을 사용하는 방법
CN105636578B (zh) 药物组合物及(2-氰乙基)膦酸二乙酯的用途
WO2007049825A1 (ja) P2x4 受容体アンタゴニスト
ES2433479T3 (es) Uso de profármacos para administración ocular intravítrea
Howland Chapter A36: Pralidoxime
Ivosevic et al. Mechanism and clinical importance of respiratory failure induced by anticholinesterases
KR20200105814A (ko) 보툴리눔 요법의 부작용 치료
HK1110219B (en) Use of prodrugs for ocular intravitreous administration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210413

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210708

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211207